EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March–December 2021

Mark A Katz iD, Madelyn Yiseth Rojas Castro iD, Giorgi Chakhunashvili, Nazibrola Chitadze, Caleb L Ward, C Jason McKnight, Héloïse Lucaccioni iD, Iris Finci, Tamila Zardiashvili, Richard Pebody, Esther Kissling, Lia Sanodze

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mark A Katz und 11 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization Regional Office for Europe, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Health Personnel, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Centers for Disease Control and Prevention, Public Health Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19 pandemic. Few data on COVID-19 vaccine effectiveness (VE) are available from middle-income countries in the WHO European Region. We evaluated primary series COVID-19 VE against laboratory-confirmed COVID-19 among HCWs in Georgia.

Methods

HCWs in six hospitals in Georgia were invited to enroll in a prospective cohort study conducted during March 19–December 5, 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT), and participants were routinely tested for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected at enrolment, and quarterly thereafter, and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We defined primary series vaccination as two doses of COVID-19 vaccine received ≥14 days before symptom onset. We estimated VE as (1-hazard ratio)*100 using a Cox proportional hazards model with vaccination status as a time-varying covariate. Estimates were adjusted by potential confounders that changed the VE estimate by more than 5%, according to the change-in-estimate approach.

Results

Overall, 1561/3849 (41%) eligible HCWs enrolled and were included in the analysis. The median age was 40 (IQR: 30–53), 1318 (84%) were female, and 1003 (64%) had laboratory evidence of prior SARS-Cov-2 infection. At enrolment, 1300 (83%) were unvaccinated; By study end, 1082 (62%) had completed a primary vaccine series (69% BNT162b2 (Pfizer-BioNTech); 22% BBIBP-CorV (Sinopharm); 9% other). During the study period, 191(12%) participants had a new PCR- or RAT-confirmed symptomatic SARS-CoV-2 infection. VE against PCR- or RAT- confirmed symptomatic SARS-CoV-2 infection was 58% (95%CI: 41; 70) for all primary series vaccinations, 68% (95%CI: 51; 79) for BNT162b2, and 40% (95%CI: 1; 64) for BBIBP-CorV vaccines. Among previously infected HCWs, VE was 58% (95%CI: 11; 80). VE against medically attended COVID-19 was 52% (95%CI: 28; 68), and VE against hospitalization was 69% (95% CI: 36; 85). During the period of predominant Delta variant circulation (July-December 2021), VE against symptomatic COVID-19 was 52% (95%CI: 30; 66).

Conclusions

Primary series vaccination with BNT162b2 and BBIBP-CorV was effective at preventing COVID-19 among HCWs, most of whom had previous infection, during a period of mainly Delta circulation. Our results support the utility of COVID-19 primary vaccine series, and the importance of increasing coverage, even among previously infected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health PersonnelCOVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyHumansFemaleMaleAdultMiddle AgedProspective StudiesGeorgia (Republic)VaccinationAntibodies, ViralBNT162 Vaccine

Substanzen

COVID-19 VaccinesAntibodies, ViralBNT162 Vaccine

Autor:innen und Institutionen

  • World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Epiconcept, Paris, France.
  • National Center for Disease Control and Public Health, Tbilisi, Georgia.
  • Public Health Institute, Tbilisi, Georgia.
  • South Caucasus Hub, World Health Organization Regional Office for Europe, Tbilisi, Georgia.
  • European Programme for Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden.

ORCID-Profile: Mark A Katz, Madelyn Yiseth Rojas Castro, Héloïse Lucaccioni

Förderung

  • World Health Organization
  • Centers for Disease Control and Prevention
  • Public Health Institute

Zitieren

APA

Katz, M. A., Rojas Castro, M. Y., Chakhunashvili, G., Chitadze, N., Ward, C. L., McKnight, C. J., Lucaccioni, H., Finci, I., Zardiashvili, T., Pebody, R., Kissling, E., & Sanodze, L. (2024). Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March–December 2021. PLOS ONE. https://doi.org/10.1371/journal.pone.0307805

Vancouver

Katz MA, Rojas Castro MY, Chakhunashvili G, Chitadze N, Ward CL, McKnight CJ, et al. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March–December 2021. PLOS ONE. 2024. doi:10.1371/journal.pone.0307805

BibTeX
@article{Katz2024,
  author = {Katz, Mark A and Rojas Castro, Madelyn Yiseth and Chakhunashvili, Giorgi and Chitadze, Nazibrola and Ward, Caleb L and McKnight, C Jason and Lucaccioni, Héloïse and Finci, Iris and Zardiashvili, Tamila and Pebody, Richard and Kissling, Esther and Sanodze, Lia},
  title = {Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March–December 2021},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307805}
}
Kostenlos starten →